Summary

The global market for Mesalamine was estimated to be worth US$ 190 million in 2024 and is forecast to a readjusted size of US$ 247 million by 2031 with a CAGR of 4.2% during the forecast period 2025-2031.
This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Mesalamine cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.
Mesalamine also known as mesalazine, or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective.

In 2024, global Mesalamine sales reached approximately 5,417 tons, with an average global market price of around US$ 35.0 per kg.
The global prevalence of IBD is rising, particularly in developed regions like North America and Europe, and increasingly in developing nations such as China and India. This increase is largely attributed to changes in lifestyle, dietary habits, and environmental factors, which are contributing to the growing demand for mesalazine.
With ulcerative colitis being the primary indication for mesalazine, the growing number of patients with this condition is directly driving market demand.
Global key players of Mesalamine are Syntese A/S, PharmaZell and Cambrex Corporation etc. The top 3 companies hold a share over 50%. The global Mesalamine are mainly produced in Europe and United States, they occupied for a share over 60%. Europe is the largest market, has a share about 43%, followed by Asia Pacific and North America, with share 31% and 12%, separately.

This report aims to provide a comprehensive presentation of the global market for Mesalamine, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Mesalamine by region & country, by Type, and by Application.
The Mesalamine market size, estimations, and forecasts are provided in terms of sales volume (Tons) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Mesalamine.

Market Segmentation
By Company
PharmaZell
Syntese A/S
Cambrex Corporation
Divis Laboratories
Chemi SpA
Ipca Laboratories
Hangzhou Brother
Lianyungang Fengheng Biopharm
Lasa Loboratory
Corden Pharma Bergamo
Erregierre SpA
CTX Lifescience
Ishita Active Pharma Ingredients
YC Biotech (Jiangsu)
Segment by Type
Purity ≥ 97%
Purity ≥ 98%
Purity ≥ 99%
Segment by Application
Tablets
Capsules
Granule
Suppository
Enema
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Mesalamine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Mesalamine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Mesalamine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Mesalamine Product Introduction
1.2 Global Mesalamine Market Size Forecast
1.2.1 Global Mesalamine Sales Value (2020-2031)
1.2.2 Global Mesalamine Sales Volume (2020-2031)
1.2.3 Global Mesalamine Sales Price (2020-2031)
1.3 Mesalamine Market Trends & Drivers
1.3.1 Mesalamine Industry Trends
1.3.2 Mesalamine Market Drivers & Opportunity
1.3.3 Mesalamine Market Challenges
1.3.4 Mesalamine Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Mesalamine Players Revenue Ranking (2024)
2.2 Global Mesalamine Revenue by Company (2020-2025)
2.3 Global Mesalamine Players Sales Volume Ranking (2024)
2.4 Global Mesalamine Sales Volume by Company Players (2020-2025)
2.5 Global Mesalamine Average Price by Company (2020-2025)
2.6 Key Manufacturers Mesalamine Manufacturing Base and Headquarters
2.7 Key Manufacturers Mesalamine Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Mesalamine
2.9 Mesalamine Market Competitive Analysis
2.9.1 Mesalamine Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Mesalamine Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Mesalamine as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Purity ≥ 97%
3.1.2 Purity ≥ 98%
3.1.3 Purity ≥ 99%
3.2 Global Mesalamine Sales Value by Type
3.2.1 Global Mesalamine Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Mesalamine Sales Value, by Type (2020-2031)
3.2.3 Global Mesalamine Sales Value, by Type (%) (2020-2031)
3.3 Global Mesalamine Sales Volume by Type
3.3.1 Global Mesalamine Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Mesalamine Sales Volume, by Type (2020-2031)
3.3.3 Global Mesalamine Sales Volume, by Type (%) (2020-2031)
3.4 Global Mesalamine Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Tablets
4.1.2 Capsules
4.1.3 Granule
4.1.4 Suppository
4.1.5 Enema
4.1.6 Others
4.2 Global Mesalamine Sales Value by Application
4.2.1 Global Mesalamine Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Mesalamine Sales Value, by Application (2020-2031)
4.2.3 Global Mesalamine Sales Value, by Application (%) (2020-2031)
4.3 Global Mesalamine Sales Volume by Application
4.3.1 Global Mesalamine Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Mesalamine Sales Volume, by Application (2020-2031)
4.3.3 Global Mesalamine Sales Volume, by Application (%) (2020-2031)
4.4 Global Mesalamine Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Mesalamine Sales Value by Region
5.1.1 Global Mesalamine Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Mesalamine Sales Value by Region (2020-2025)
5.1.3 Global Mesalamine Sales Value by Region (2026-2031)
5.1.4 Global Mesalamine Sales Value by Region (%), (2020-2031)
5.2 Global Mesalamine Sales Volume by Region
5.2.1 Global Mesalamine Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Mesalamine Sales Volume by Region (2020-2025)
5.2.3 Global Mesalamine Sales Volume by Region (2026-2031)
5.2.4 Global Mesalamine Sales Volume by Region (%), (2020-2031)
5.3 Global Mesalamine Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Mesalamine Sales Value, 2020-2031
5.4.2 North America Mesalamine Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Mesalamine Sales Value, 2020-2031
5.5.2 Europe Mesalamine Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Mesalamine Sales Value, 2020-2031
5.6.2 Asia Pacific Mesalamine Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Mesalamine Sales Value, 2020-2031
5.7.2 South America Mesalamine Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Mesalamine Sales Value, 2020-2031
5.8.2 Middle East & Africa Mesalamine Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Mesalamine Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Mesalamine Sales Value and Sales Volume
6.2.1 Key Countries/Regions Mesalamine Sales Value, 2020-2031
6.2.2 Key Countries/Regions Mesalamine Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Mesalamine Sales Value, 2020-2031
6.3.2 United States Mesalamine Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Mesalamine Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Mesalamine Sales Value, 2020-2031
6.4.2 Europe Mesalamine Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Mesalamine Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Mesalamine Sales Value, 2020-2031
6.5.2 China Mesalamine Sales Value by Type (%), 2024 VS 2031
6.5.3 China Mesalamine Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Mesalamine Sales Value, 2020-2031
6.6.2 Japan Mesalamine Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Mesalamine Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Mesalamine Sales Value, 2020-2031
6.7.2 South Korea Mesalamine Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Mesalamine Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Mesalamine Sales Value, 2020-2031
6.8.2 Southeast Asia Mesalamine Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Mesalamine Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Mesalamine Sales Value, 2020-2031
6.9.2 India Mesalamine Sales Value by Type (%), 2024 VS 2031
6.9.3 India Mesalamine Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 PharmaZell
7.1.1 PharmaZell Company Information
7.1.2 PharmaZell Introduction and Business Overview
7.1.3 PharmaZell Mesalamine Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 PharmaZell Mesalamine Product Offerings
7.1.5 PharmaZell Recent Development
7.2 Syntese A/S
7.2.1 Syntese A/S Company Information
7.2.2 Syntese A/S Introduction and Business Overview
7.2.3 Syntese A/S Mesalamine Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Syntese A/S Mesalamine Product Offerings
7.2.5 Syntese A/S Recent Development
7.3 Cambrex Corporation
7.3.1 Cambrex Corporation Company Information
7.3.2 Cambrex Corporation Introduction and Business Overview
7.3.3 Cambrex Corporation Mesalamine Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Cambrex Corporation Mesalamine Product Offerings
7.3.5 Cambrex Corporation Recent Development
7.4 Divis Laboratories
7.4.1 Divis Laboratories Company Information
7.4.2 Divis Laboratories Introduction and Business Overview
7.4.3 Divis Laboratories Mesalamine Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Divis Laboratories Mesalamine Product Offerings
7.4.5 Divis Laboratories Recent Development
7.5 Chemi SpA
7.5.1 Chemi SpA Company Information
7.5.2 Chemi SpA Introduction and Business Overview
7.5.3 Chemi SpA Mesalamine Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Chemi SpA Mesalamine Product Offerings
7.5.5 Chemi SpA Recent Development
7.6 Ipca Laboratories
7.6.1 Ipca Laboratories Company Information
7.6.2 Ipca Laboratories Introduction and Business Overview
7.6.3 Ipca Laboratories Mesalamine Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Ipca Laboratories Mesalamine Product Offerings
7.6.5 Ipca Laboratories Recent Development
7.7 Hangzhou Brother
7.7.1 Hangzhou Brother Company Information
7.7.2 Hangzhou Brother Introduction and Business Overview
7.7.3 Hangzhou Brother Mesalamine Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Hangzhou Brother Mesalamine Product Offerings
7.7.5 Hangzhou Brother Recent Development
7.8 Lianyungang Fengheng Biopharm
7.8.1 Lianyungang Fengheng Biopharm Company Information
7.8.2 Lianyungang Fengheng Biopharm Introduction and Business Overview
7.8.3 Lianyungang Fengheng Biopharm Mesalamine Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Lianyungang Fengheng Biopharm Mesalamine Product Offerings
7.8.5 Lianyungang Fengheng Biopharm Recent Development
7.9 Lasa Loboratory
7.9.1 Lasa Loboratory Company Information
7.9.2 Lasa Loboratory Introduction and Business Overview
7.9.3 Lasa Loboratory Mesalamine Sales, Revenue, Price and Gross Margin (2020-2025)
7.9.4 Lasa Loboratory Mesalamine Product Offerings
7.9.5 Lasa Loboratory Recent Development
7.10 Corden Pharma Bergamo
7.10.1 Corden Pharma Bergamo Company Information
7.10.2 Corden Pharma Bergamo Introduction and Business Overview
7.10.3 Corden Pharma Bergamo Mesalamine Sales, Revenue, Price and Gross Margin (2020-2025)
7.10.4 Corden Pharma Bergamo Mesalamine Product Offerings
7.10.5 Corden Pharma Bergamo Recent Development
7.11 Erregierre SpA
7.11.1 Erregierre SpA Company Information
7.11.2 Erregierre SpA Introduction and Business Overview
7.11.3 Erregierre SpA Mesalamine Sales, Revenue, Price and Gross Margin (2020-2025)
7.11.4 Erregierre SpA Mesalamine Product Offerings
7.11.5 Erregierre SpA Recent Development
7.12 CTX Lifescience
7.12.1 CTX Lifescience Company Information
7.12.2 CTX Lifescience Introduction and Business Overview
7.12.3 CTX Lifescience Mesalamine Sales, Revenue, Price and Gross Margin (2020-2025)
7.12.4 CTX Lifescience Mesalamine Product Offerings
7.12.5 CTX Lifescience Recent Development
7.13 Ishita Active Pharma Ingredients
7.13.1 Ishita Active Pharma Ingredients Company Information
7.13.2 Ishita Active Pharma Ingredients Introduction and Business Overview
7.13.3 Ishita Active Pharma Ingredients Mesalamine Sales, Revenue, Price and Gross Margin (2020-2025)
7.13.4 Ishita Active Pharma Ingredients Mesalamine Product Offerings
7.13.5 Ishita Active Pharma Ingredients Recent Development
7.14 YC Biotech (Jiangsu)
7.14.1 YC Biotech (Jiangsu) Company Information
7.14.2 YC Biotech (Jiangsu) Introduction and Business Overview
7.14.3 YC Biotech (Jiangsu) Mesalamine Sales, Revenue, Price and Gross Margin (2020-2025)
7.14.4 YC Biotech (Jiangsu) Mesalamine Product Offerings
7.14.5 YC Biotech (Jiangsu) Recent Development
8 Industry Chain Analysis
8.1 Mesalamine Industrial Chain
8.2 Mesalamine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Mesalamine Sales Model
8.5.2 Sales Channel
8.5.3 Mesalamine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer